Cargando…
Nonvitamin K Antagonist Oral Anticoagulants Versus Warfarin in Atrial Fibrillation Patients and Risk of Dementia: A Nationwide Propensity‐Weighted Cohort Study
BACKGROUND: It is unclear whether nonvitamin K antagonist oral anticoagulants (NOACs) can mitigate dementia development in atrial fibrillation. We compared dementia development among users of NOACs or warfarin in patients with atrial fibrillation with no prior neurological diagnoses. METHODS AND RES...
Autores principales: | Søgaard, Mette, Skjøth, Flemming, Jensen, Martin, Kjældgaard, Jette Nordstrøm, Lip, Gregory Y. H., Larsen, Torben Bjerregaard, Nielsen, Peter Brønnum |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585353/ https://www.ncbi.nlm.nih.gov/pubmed/31138001 http://dx.doi.org/10.1161/JAHA.118.011358 |
Ejemplares similares
-
Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study
por: Nielsen, Peter Brønnum, et al.
Publicado: (2017) -
Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study
por: Larsen, Torben Bjerregaard, et al.
Publicado: (2016) -
Non–Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Atrial Fibrillation Patients With Intracerebral Hemorrhage
por: Nielsen, Peter Brønnum, et al.
Publicado: (2019) -
Bleeding Complications in Anticoagulated Patients With Atrial Fibrillation and Sepsis: A Propensity‐Weighted Cohort Study
por: Søgaard, Mette, et al.
Publicado: (2017) -
Risk of recurrence and bleeding in patients with cancer‐associated venous thromboembolism treated with rivaroxaban: A nationwide cohort study
por: Søgaard, Mette, et al.
Publicado: (2019)